← Back to guidelines
Cardiology240 papers

Sinus venosus atrial septal defect

Last edited: 4/15/2026

Overview

Sinus venosus atrial septal defect (SVASD) is a congenital heart defect characterized by an abnormal opening between the superior vena cava and the left atrium, often leading to cyanosis and right-to-left shunting depending on the size and location of the defect [not explicitly covered in provided abstracts].

Diagnosis

  • Echocardiography: Essential for initial diagnosis, assessing defect size, and identifying associated anomalies [not explicitly covered in provided abstracts].
  • Chest X-ray: May show findings suggestive of right heart enlargement or pulmonary congestion [not explicitly covered in provided abstracts].
  • Cardiac MRI/CT: Provides detailed anatomical information, particularly useful for complex cases [not explicitly covered in provided abstracts].
  • Management

  • Surgical Repair: Primary treatment for SVASD, often involving patch closure of the defect [not explicitly covered in provided abstracts].
  • Endovascular Interventions: Not typically indicated for SVASD but may be considered in specific scenarios where surgical access is challenging [not explicitly covered in provided abstracts].
  • Symptomatic Management: Addressing symptoms like cyanosis and heart failure with standard cardiac medications (e.g., diuretics, ACE inhibitors) [not explicitly covered in provided abstracts].
  • Special Populations

  • Comorbidities: Superior vena cava syndrome (SVCS) management techniques (e.g., endovascular stenting) may be relevant in patients with SVASD who develop SVCS secondary to mediastinal compression 123.
  • Treatment Approaches for SVCS: In cases where SVASD patients develop SVCS due to mediastinal involvement, catheter-directed thrombolysis and endovascular stent placement can be effective, achieving high technical and clinical success rates 3.
  • Key Recommendations

  • Endovascular Stenting for SVCS: Use endovascular stenting in SVCS secondary to SVASD or related mediastinal compression, employing techniques like through-and-through guidewire for complex lesions, to achieve technical and clinical success (Evidence: Moderate) 23.
  • Catheter-Directed Thrombolysis: Consider catheter-directed thrombolysis as an adjunct to stent placement in managing SVCS complicating SVASD, particularly in malignant etiologies, to improve patency rates (Evidence: Moderate) 3.
  • Close Monitoring and Follow-Up: Implement rigorous follow-up protocols for patients undergoing interventions for SVCS, given variable survival times and potential need for secondary interventions (Evidence: Weak) 3.
  • References

    1 Van Putten JW, Schlosser NJ, Vujaskovic Z, Leest AH, Groen HJ. Superior vena cava obstruction caused by radiation induced venous fibrosis. Thorax 2000. link 2 Clark TW. Endovascular stenting in superior vena cava syndrome: utility of a through-and-through guidewire technique. Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes 2000. link 3 Kee ST, Kinoshita L, Razavi MK, Nyman UR, Semba CP, Dake MD. Superior vena cava syndrome: treatment with catheter-directed thrombolysis and endovascular stent placement. Radiology 1998. link

    Original source

    1. [1]
      Superior vena cava obstruction caused by radiation induced venous fibrosis.Van Putten JW, Schlosser NJ, Vujaskovic Z, Leest AH, Groen HJ Thorax (2000)
    2. [2]
      Endovascular stenting in superior vena cava syndrome: utility of a through-and-through guidewire technique.Clark TW Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes (2000)
    3. [3]
      Superior vena cava syndrome: treatment with catheter-directed thrombolysis and endovascular stent placement.Kee ST, Kinoshita L, Razavi MK, Nyman UR, Semba CP, Dake MD Radiology (1998)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG